Michael Severino, Tessera Therapeutics CEO

Af­ter rais­ing half a bil­lion dol­lars, a se­cre­tive biotech gives an ear­ly look at its gene edit­ing pipeline

A se­cre­tive biotech start­up de­vel­op­ing a new form of gene edit­ing is start­ing to give cu­ri­ous sci­en­tists a peek at its pipeline — with­out ful­ly di­vulging how its close­ly scru­ti­nized tech­nol­o­gy works.

On Fri­day, Tessera Ther­a­peu­tics an­nounced pre­lim­i­nary da­ta from five pre­clin­i­cal pro­grams us­ing its “gene writ­ers” to tweak spe­cif­ic let­ters or in­sert en­tire­ly new se­quences of DNA. The tech­niques are part of a larg­er move­ment in the gene edit­ing field to de­vel­op tools that could treat near­ly any con­ceiv­able ge­net­ic dis­ease, and Tessera is one of its top con­tenders.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.